Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F17%3A43889128" target="_blank" >RIV/60162694:G44__/17:43889128 - isvavai.cz</a>

Alternative codes found

RIV/62690094:18470/17:50013395 RIV/00179906:_____/17:10361557

Result on the web

<a href="https://www.future-science.com/doi/10.4155/fmc-2017-0030" target="_blank" >https://www.future-science.com/doi/10.4155/fmc-2017-0030</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4155/fmc-2017-0030" target="_blank" >10.4155/fmc-2017-0030</a>

Result language

angličtina

Original language name

Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors

Original language description

Prolyl oligopeptidase (POP), also called prolyl endopeptidase, is a cytosolic enzyme investigated by several research groups. It has been proposed to play an important role in physiological processes such as modulation of the levels of several neuronal peptides and hormones containing a proline residue. Due to its proteolytic activity and physiological role in cell signaling pathways, inhibition of POP offers an emerging approach for the treatment of Alzheimer&apos;s and Parkinson&apos;s diseases as well as other diseases related to cognitive impairment. Furthermore, it may also represent an interesting target for treatment of neuropsychiatric disorders, and as an antiangiogenesis or antineoplastic agent. In this review paper, we summarized naturally occurring POP inhibitors together with peptide-like inhibitors and their biological effects. Some of them have shown promising results and interesting pharmacological profiles. However, to date, there is no POP inhibitor available on the market although several clinical trials have been undertaken.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Future Medicinal Chemistry

ISSN

1756-8919

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

24

Pages from-to

1015-1038

UT code for WoS article

000406048700006

EID of the result in the Scopus database

2-s2.0-85021260683